SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Mirati Therapeutics, Inc.® (Nasdaq – MRTX)
BALA CYNWYD – October 9, 2023 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Mirati Therapeutics, Inc.® (“Mirati” or the “Company”) (Nasdaq – MRTX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Bristol Myers Squibb (NYSE – BMY) for $58.00 per share in cash for each share of Mirati held. The deal has a total equity value of $4.8 billion corresponding to an enterprise value of approximately $3.7 billion, which accounts for approximately $1.1 billion of Mirati cash. Each Mirati stockholder will also receive one non-tradeable CVR per Mirati share, which will entitle its holder to receive a one-time potential payment of $12.00 in cash, for a total value of approximately $1.0 billion.
The investigation concerns whether the Mirati Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Bristol Myers Squibb is paying fair value to shareholders of the Company.
If you own shares of Mirati stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.